Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report), Day One Biopharmaceuticals (DAWN – Research Report) and Masimo (MASI – Research Report).
Sarepta Therapeutics (SRPT)
RBC Capital analyst Brian Abrahams maintained a Buy rating on Sarepta Therapeutics today and set a price target of $148.00. The company’s shares closed last Tuesday at $82.61.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $129.75 average price target, a 58.3% upside from current levels. In a report issued on November 20, Wedbush also initiated coverage with a Buy rating on the stock with a $224.00 price target.
See the top stocks recommended by analysts >>
Day One Biopharmaceuticals (DAWN)
Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Day One Biopharmaceuticals today and set a price target of $45.00. The company’s shares closed last Tuesday at $11.59, close to its 52-week low of $9.67.
According to TipRanks.com, Catanzaro is a 2-star analyst with an average return of
Currently, the analyst consensus on Day One Biopharmaceuticals is a Moderate Buy with an average price target of $36.00, implying a 204.6% upside from current levels. In a report issued on November 15, J.P. Morgan also maintained a Buy rating on the stock with a $31.00 price target.
Masimo (MASI)
In a report released today, Jason Bednar from Piper Sandler maintained a Hold rating on Masimo, with a price target of $70.00. The company’s shares closed last Tuesday at $92.89, close to its 52-week low of $75.22.
According to TipRanks.com, Bednar ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Masimo is a Moderate Buy with an average price target of $89.00, implying a -6.0% downside from current levels. In a report issued on November 15, Wells Fargo also maintained a Hold rating on the stock with a $81.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SRPT:
- Sarepta initiated with an Outperform at Wedbush
- Catalent price target lowered to $55 from $58 at RBC Capital
- Insiders Load Up on These 2 ‘Strong Buy’ Stocks — Here’s Why You Should Pay Attention
- JPMorgan healthcare/biotech analysts hold analyst/industry conference call
- Biotech Alert: Searches spiking for these stocks today
